ArticleAging2013
Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors.
Article in Aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 86 citations in OpenAlex.
- Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.Cancer immunology research · 2019Trial
- Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Integrating evolutionary theory into a framework for the mechanistic evaluation of candidate anti-aging interventions.Frontiers in aging · 2026Article
- Review
- Article
- Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives.Antibiotics (Basel, Switzerland) · 2024Review
- Article
- Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?Aging · 2023Article
- Rapamycin, the only drug that has been consistently demonstrated to increase mammalian longevity. An update.Experimental gerontology · 2023Review
- Acarbose suppresses symptoms of mitochondrial disease in a mouse model of Leigh syndrome.Nature metabolism · 2023Article
- Targeting the biology of aging with mTOR inhibitors.Nature aging · 2023Review
- Cancer prevention with rapamycin.Oncotarget · 2023Article
- Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice.Aging · 2022Article
- Therapeutic Antiaging Strategies.Biomedicines · 2022Review
- Pharmacological Approaches to Decelerate Aging: A Promising Path.Oxidative medicine and cellular longevity · 2022Review
- Anti-aging: senolytics or gerostatics (unconventional view).Oncotarget · 2021Review
- Effect of rapamycin on aging and age-related diseases-past and future.GeroScience · 2021Review
- Rapamycin Extends Life Span in ApcClinical colorectal cancer · 2021Article
- Article
- The goal of geroscience is life extension.Oncotarget · 2021Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic treatment of mice with an enterically released formulation of rapamycin (eRapa) extends median and maximum life span, partly by attenuating cancer. The mechanistic basis of this response is not known. To gain a better understanding of thesein vivo effects, we used a defined preclinical model of neuroendocrine cancer, Rb1+/- mice. Previous results showed that diet restriction (DR) had minimal or no effect on the lifespan of Rb1+/- mice, suggesting that the beneficial response to DR is dependent on pRb1. Since long-term eRapa treatment may at least partially mimic chronic DR in lifespan extension, we predicted that it would have a minimal effect in Rb1+/- mice. Beginning at 9 weeks of age until death, we fed Rb1+/- mice a diet without or with eRapa at 14 mg/kg food, which results in an approximate dose of 2.24 mg/kg body weight per day, and yielded rapamycin blood levels of about 4 ng/ml. Surprisingly, we found that eRapa dramatically extended life span of both female and male Rb1+/- mice, and slowed the appearance and growth of pituitary and decreased the incidence of thyroid tumors commonly observed in these mice. In this model, eRapa appears to act differently than DR, suggesting diverse mechanisms of action on survival and anti-tumor effects. In particular the beneficial effects of rapamycin did not depend on the dose of Rb1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.